All In Biotech

Drug Trial Radar · NCT03945318

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

103

Actual

Start

Apr 8, 2019

Primary completion

Jun 10, 2026

Study completion Jun 10, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).

Conditions

  • IgA Nephropathy

Interventions

  • BION-1301 Single DoseDrug

    A single IV infusion infusion of BION-1301 at doses ranging from 10 to 1350 mg, administered once

  • Placebo Single DoseDrug

    A single IV infusion of placebo

  • BION-1301 Multiple DosesDrug

    Part 2: Multiple IV infusions of BION 1301 administered every 2 weeks (Q2W) at doses of 50 mg, 150 mg or 450 mg for up to 3 doses. Part 3: Repeated dosing of BION 1301: 450 mg IV Q2W for ≥24 weeks followed by 600 mg SC Q2W, or 600 mg SC Q2W throughout.

  • Placebo Multiple DosesDrug

    Multiple IV infusions of placebo administered every 2 weeks for up to 3 doses

  • BION-1301 Single DoseDrug

    600 mg SC injection every 2 weeks (Q2W) for retreatment, administered via vials or pre-filled syringes (PFS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs) and treatment-emergent serious adverse events (SAEs)Time frame: Up to 276 weeks
  2. Change from baseline in systolic and diastolic blood pressureTime frame: Baseline and up to 276 weeks.
  3. Change from baseline in estimated glomerular filtration rate (eGFR)Time frame: Baseline and up to 276 weeks

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Amicis Research Center

    Northridge, California

  • Colorado Kidney Care, P.C.

    Denver, Colorado

  • Nephrology Associates of Central Florida

    Orlando, Florida

  • Elixia Tampa, LLC

    Tampa, Florida

  • New York Nephrology

    Clifton Park, New York

  • Chris Sholer, P.C.

    Oklahoma City, Oklahoma

  • Liberty Research Center

    Arlington, Texas

  • Liberty Research Center

    Dallas, Texas

  • Prolato Clinical Research Center

    Houston, Texas

  • Soon Chun Hyang University Hospital Cheonan

    Cheonan, Chungcheongnam-do, South Korea

  • Hallym University Sacred Heart Hospital

    Anyang-si, Gyeonggi-do, South Korea

  • National Health Insurance Service Ilsan Hospital

    Goyang-si, Gyeonggi-do, South Korea

  • Hanyang University Guri Hostpital

    Guri-si, Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • PAREXEL Early Phase Clinical Unit

    London, United Kingdom

  • Liverpool University Hospital NHS Foundation Trust

    Liverpool, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.